Dose of Remimazolam in Children for Intubation (DRIP)

Zhihong LU

Status: Not yet enrolling

Conditions: Anesthesia

Treatments: Drug: Remimazolam

Study type: Interventional

Funder types: Other

Identifiers

NCT06170918

XJH-A-20231120

Details and patient eligibility

About

Remimazolam has demonstrated the potential as a valuable medication for procedural sedation and general anesthesia. However, half effective dose of remimazolam required to prevent cardiovascular response to tracheal intubation when combined with fentanyl in pediatric patients is still unknown.

Enrollment: 40 estimated patients

Sex: All

Ages: 3 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age from 3 to 12 years old
• patients scheduled for surgery under general anesthesia
• Body mass index in the range of 5% -95% of the same age group
• Consent was obtained from the patient and the family members, and an informed consent form was signed

Exclusion criteria

• American Society of Anesthesiologists status ≥3
• patients who cannot cooperate with intravenous anesthesia induction
• patients with risk of difficult airway
• patients who are allergic to benzodiazepines
• patients with neurological dysfunction
• Participate involved in other clinical investigators within 3 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

remimazolam

Experimental group

Description:

Remimazolam is given for anesthesia induction. The initial dosage is 0.4mg/kg, and the interval dosage is 0.02mg/kg.

Treatment:

Drug: Remimazolam